Skip to main content
Premium Trial:

Request an Annual Quote

Empire Genomics Partners with Quadpharma to Manufacture ASRs

NEW YORK (GenomeWeb) – Empire Genomics said today it has tapped Quadpharma to manufacture analyte-specific reagents using current good manufacturing principles for its clients in the research, clinical, and pharmaceutical industries.

Empire, located in Buffalo, NY, said it partnered with the Clarence, NY-based contract manufacturer to meet a growing demand for GMP-manufactured ASRs, and noted that the companies have completed their first batch of products. The company said its clients are increasingly requesting that more stringent quality controls be applied in early phases of their research and development and clinical services to meet requirements for test performance.

"This relationship is critical in continuing to ensure that we meet the needs of our customers from research through clinical trials and ultimately the launching of companion diagnostic tests," Empire Genomics President and CEO Anthony Johnson said in a statement .

He added that the partnership is currently in its first phase and that Empire will work with Quadpharma to manufacture in vitro diagnostic products in the future.

Financial terms of the agreement were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.